Clinical Trial Update: Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Ypeginterferon Alfa-2b in chronic hepatitis C has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ypeginterferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED